Search
Roxithromycin
go.drugbank.com/drugs/DB00778ApprovedInvestigationalWithdrawnRoxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis.
Scopolamine
go.drugbank.com/drugs/DB00747ApprovedInvestigational[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants. … [A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578]
Choline C 11
go.drugbank.com/drugs/DB09277Approved[A32041] It was developed by MCPRF and FDA first approved in September 2012.
Berberine
go.drugbank.com/drugs/DB04115ApprovedInvestigationalWithdrawnIt is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.
Abciximab
go.drugbank.com/drugs/DB00054ApprovedWithdrawnAbciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules
Arsenic trioxide
go.drugbank.com/drugs/DB01169ApprovedInvestigationalArsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic ...
Technetium Tc-99m succimer
go.drugbank.com/drugs/DB09436ApprovedIt works by binding to the cortical region of the kidneys. Technetium Tc-99m succimer is used with gamma scintigraphy or single-photon emission computed tomography (SPECT). … [L40558] The use of technetium Tc-99m succimer for the detection of kidney cortical defects was first approved by the FDA on February 23, 2022, under the market name NephroScan.[L40573]
Liotrix
go.drugbank.com/drugs/DB01583ApprovedIt consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. … Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion.
Tetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedWF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. … The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the
Temoporfin
go.drugbank.com/drugs/DB11630ApprovedIt was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.